Proposed preliminary core set measures for disease outcome assessment in adult and juvenile idiopathic inflammatory myopathies

Rheumatology

Volumn 40, Issue 11, 2001, Pages 1262-1273

  Miller, F W ^a,m   Rider, L G ^a   Chung, Y L ^b   Cooper, R ^c   Danko, K ^d   Farewell, V ^e   Lundberg, I ^f   Morrison, C ^g   Oakley, L ^h   Oakley, I ^h   Pilkington, C ⁱ   Vencovsky, J ^j   Vincent, K ^k   Scott, D L ^g   Isenberg, D A ^l  

^a CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

^b HAMMERSMITH HOSPITAL   (United Kingdom)

^c HOPE HOSPITAL   (United Kingdom)

^d UNIVERSITY OF DEBRECEN   (Hungary)

^e UNIVERSITY COLLEGE LONDON   (United Kingdom)

^f KAROLINSKA INSTITUTE   (Sweden)

^g KING S COLLEGE HOSPITAL   (United Kingdom)

^h Dermatomyositis and Polymyositis Support Group   (United Kingdom)

ⁱ MIDDLESEX HOSPITAL   (United Kingdom)

^j INSTITUTE OF RHEUMATOLOGY   (Czech Republic)

^k KING'S COLLEGE LONDON   (United Kingdom)

^l UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^m NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

more..

Author keywords

Idiopathic inflammatory myopathies; Outcome measures

Indexed keywords

MUSCLE ENZYME;

ADOLESCENT; ADULT; ARTICLE; CHILD; CLINICAL STUDY; CONTROLLED STUDY; DERMATOMYOSITIS; DISEASE ACTIVITY; DISEASE DURATION; HEALTH SURVEY; HUMAN; IDIOPATHIC DISEASE; INCLUSION BODY MYOSITIS; INFLAMMATORY DISEASE; MEDICAL ASSESSMENT; MEDICAL SPECIALIST; MUSCLE STRENGTH; MYOPATHY; ORGANIZATION; OUTCOMES RESEARCH; PATHOLOGICAL ANATOMY; PATIENT CARE; PEDIATRICS; PHYSICAL ACTIVITY; PHYSICIAN; POLYMYOSITIS; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; STANDARDIZATION;

EID: 0035179180     PISSN: 14620324     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (57)

1. Incidence of polymyositis-dermatomyositis: A 20-year study of hospital diagnosed cases in Allegheny County, PA 1963-1982
2. A new approach to the classification of idiopathic inflammatory myopathy: Myositis-specific autoantibodies define useful homogeneous patient groups
3. The treatment of myositis. How to approach resistant disease
4. Azathioprine with prednisone for polymyositis. A controlled, clinical trial
5. Controlled trial of plasma exchange and leukapheresis in polymyositis and dermatomyositis
6. A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis
7. Muscular strength as an index of response to therapy in childhood dermatomyositis
8. Validation of manual muscle testing (MMT) in the assessment of juvenile dermatomyositis (JDM)
9. Juvenile dermatomyositis at diagnosis: Clinical characteristics of 79 children
10. Medium- and long-term functional outcomes in a multicenter cohort of children with juvenile dermatomyositis
11. Association of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index with measures of disease activity and health status in patients with systemic lupus erythematosus
12. Assessment of disease activity and its sequelae in children and adults with myositis
13. Musculoskeletal Clinical Metrology
14. Prednisone and azathioprine for polymyositis: Long-term followup
15. Cyclosporin in juvenile dermatomyositis
16. The failure of intravenous cyclophosphamide therapy in refractory idiopathic inflammatory myopathy
17. Intravenous immunoglobulin for polymyositis and dermatomyositis
18. Treatment of dermatomyositis with intravenous gammaglobulin
19. Efficacy of intravenous gammaglobulin therapy in chronic refractory polymyositis and dermatomyositis: An open study with 20 adult patients
20. The treatment of inclusion body myositis: A retrospective review and a randomized, prospective trial of immunosuppressive therapy
21. Intravenous gamma globulin as first line therapy in polymyositis and dermatomyositis: An open study in 11 adult patients
22. Treatment of inclusion-body myositis with IVIg: A double-blind, placebo-controlled study
23. Treatment of refractory myositis: A randomized crossover study of two new cytotoxic regimens
24. Immunoglobulin therapy in inflammatory myopathies
25. A pilot study: Use of fludarabine for refractory dermatomyositis and polymyositis, and examination of endpoint measures
26. Tacrolimus in refractory polymyositis with interstitial lung disease
27. Cyclosporine A versus methotrexate in the treatment of polymyositis and dermatomyositis
28. Development of validated disease activity and damage indices for the juvenile idiopathic inflammatory myopathies: I. Physician, parent, and patient global assessments
29. Preliminary validation of abbreviated manual muscle testing (MMT) in the assessment of juvenile dermatomyositis (JDM)
30. Measuring disability in juvenile dermatomyositis: Validity of the childhood health assessment questionnaire
31. Validation of the Childhood Health Assessment Questionnaire (CHAQ) in the juvenile idiopathic inflammatory myopathies
32. Dysphagia as the only manifestation of inclusion body myositis
33. Development of validated disease activity and damage indices for the juvenile idiopathic inflammatory myopathies. II. The Childhood Myositis Assessment Scale (CMAS): A quantitative tool for the evaluation of muscle function
34. A functional index in myositis
35. Relationships among laboratory tests and global disease activity assessments in juvenile dermatomyositis
36. Laboratory evaluation of the inflammatory myopathies
37. MR imaging in children with dermatomyositis: Musculoskeletal findings and correlation with clinical and laboratory findings
38. Magnetic resonance imaging detection of occult skin and subcutaneous abnormalities in juvenile dermatomyositis. Implications for diagnosis and therapy
39. Magnetic resonance imaging in the idiopathic inflammatory myopathies
40. Identifying skin lesions in dermatomyositis: Inter-rater reliability of a new cutaneous assessment tool
41. Nailfold capillaries as indicators of disease activity in juvenile idiopathic inflammatory myopathies
42. Swallowing and oral motor abnormalities are frequent in juvenile idiopathic inflammatory myopathies
43. Simple method for measurement of lower extremity muscle strength
44. MRI directed muscle biopsy for assessment of juvenile dermatomyositis response to therapy: Comparison of initial and follow-up biopsies using a histological rating scale evaluating disease severity/chronicity
45. Monitoring disease activity in juvenile dermatomyositis: The role of von Willebrand factor and muscle enzymes
46. The idiopathic inflammatory myopathies: Spectrum of MR imaging findings
47. Use of magnetic resonance imaging and P-31 magnetic resonance spectroscopy to detect and quantify muscle dysfunction in the amyopathic and myopathic variants of dermatomyositis
48. The BILAG index: A reliable and valid instrument for measuring clinical disease activity in systemic lupus erythematosus
49. Validity of a vasculitis activity index for systemic necrotizing vasculitis
50. A longitudinal study of functional disability in a national cohort of patients with polymyositis/dermatomyositis
51. In vivo proton magnetic resonance spectroscopy in polymyositis and dermatomyositis: A preliminary study
52. The SF-36 health survey questionnaire: An outcome measure suitable for routine use within the NHS
53. The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus
54. Update on outcome assessment in rheumatic disorders
55. Health status in inflammatory muscle disease
56. The PedsQL: Measurement model for the pediatric quality of life inventory
57. The CHQ User's Manual